ArticleScientific reports2025
Mass fabrication of PDMS microfluidic devices by injection molding and applications in sensitive 3D spheroid and explant culture.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microfluidics for Blood Disorders and Hematological Disease Monitoring and Modeling.International journal of molecular sciences · 2026Review
- Liver-on-a-Chip (LoC) Models: Case Studies of Academic Platforms and Commercial Products.Molecular pharmaceutics · 2026Review
- Endocrine and cardiovascular consequences of plasticiser exposure: a narrative review from the thyroid- cardiac axis perspective.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study investigates the use of industrial-grade polydimethylsiloxane (PDMS) for mass production of microfluidic chips through Liquid Silicone Rubber Injection Molding (LSR-IM) technologies. Injection molding of PDMS is ubiquitous in the automotive and aerospace industries. Yet, it is not currently applied to large-scale production of microfluidic devices. Here, we manufactured PDMS microfluidics devices using industrial IM systems and measured the values of several physicochemical properties of PDMS important in microfluidics. For the two grades of injection-moldable PDMS studied, properties were found close to those of the standard Sylgard 184 PDMS, except Young's modulus, which varied from 66% to 250% of the Sylgard 184 value and the absorption of small molecules, which was lower or equal to that within Sylgard 184. Yet, the main benefits of LSR-IM production lie in its systematic process, resulting in an increase in reproducibility of both PDMS surface and bulk properties by decreasing the variance within and between production batches of several variables: Young's modulus (30-fold), oxygen permeation (10-fold), mean fluorescence intensity of Nile Red (5-fold). Emphasis on biocompatibility of LSR-IM was evaluated by culturing complex and sensitive 3D biology models (tumor spheroids and explants) in injection-molded PDMS devices. We observed no significant differences in cell proliferation relative to samples cultured on conventional Sylgard 184 PDMS devices. Overall, these findings open a direct path from benchtop prototyping to industrialization of PDMS-based microfluidic devices for applications in healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.